The EU-funded DREAMS project, now including University College London, aims to accelerate the discovery of treatments for rare neuromuscular disorders. By leveraging AI-based drug discovery and advanced screening methods, the project targets five specific diseases, including Duchenne muscular dystrophy and centronuclear myopathy.